Fireman B.V. (IFRX) Stock Price, Quote & News

Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological pro...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 3641 508 180

Website: www.inflarx.de

Address:

Winzerlaer Str. 2, Jena, Germany

morgueana Jul. 3 at 6:42 PM

$IFRX I want investors and IFRX top brass to really consider exploring CSU as one of the best indications to pursue with Izi in the near future. Celldex is getting really clean data with it's drug Barzo and is on it's way to likely FDA approval. The beauty of pursuing CSU is that it is treated with multiple classes of combination anti-histamines and not oral steroids, hence studies are not complicated by almost impossible design protocols with the FDA involving steroid tapering and discontinuation. This is a big negative going forward i PG, HS or AAV studies! The 904 (Izi) studies had excellent efficacy and safety data in the P2 studies. Niels said the reason the curve dropped off with the 240mg dose was the inclusion of AE patients that didn't have CSU. (Camilla, Camilla!) Just some thoughts. Also as a major shareholder, I am uncomfortable with us internally filling the all-important CMO role when we have a scientific founder in Niels at our helm!!??

3 · Reply

FlowerInTheCellar Jul. 3 at 4:14 PM

$IFRX @MrCompassion, A very interesting basic research paper on C5a biology was published today in *Cell Research*. Since InflaRx is working within the same biological system, the publication may be of interest to those here who enjoy following the underlying science. I'm sharing the newly published article here. If you're willing, perhaps you could provide a summary of your thoughts in a way that's easy for everyone to understand. I think many people in the forum would appreciate your perspective. https://www.nature.com/articles/s41422-026-01273-1

0 · Reply

FlowerInTheCellar Jul. 3 at 1:51 PM

$IFRX https://ancavasculitisnews.com/news/tavneos-developer-now-advancing-2-new-vasculitis-treatments-europe/ Written by Andrea Lobo, PhD | July 1, 2026 Quick heads-up from across the pond: The US patient and expert portal ANCA Vasculitis News just covered how InflaRx is responding to the EMA's recommendation on Tavneos. The fact that a major patient-focused outlet is picking this up so quickly shows just how high the demand for alternatives is. Key takeaways: Approval Pathways: InflaRx is looking to talk directly with the EMA to explore alternative regulatory pathways for its own pipeline (vilobelimab and izicopan). Izicopan (Oral): Preparations for the Phase 2 trial remain fully on schedule. Vilobelimab (Antibody): Ready for Phase 3. The goal remains to tackle inflammation while reducing the need for heavy steroids. Chart-wise, the trend looks constructive after breaking above the 50-day moving average. Let's see how the EMA talks go.

0 · Reply

Monkey82 Jul. 3 at 1:44 PM

$IFRX https://seekingalpha.com/news/4609828-strong-buy-at-under-10-the-highest-quant-rated-bargain-stocks-right-now

0 · Reply

Barkingdogs Jul. 3 at 12:32 PM

$IFRX

0 · Reply

nickmick Jul. 2 at 4:40 PM

$IFRX My personal suspicion is that AMGN will wriggle out of the Avacopan debacle with the help of cunning lawyers and new data interpretations. What do the people who get left behind matter when billions of dollars in investments and the company's reputation are at stake? Of course, I could be wrong, but the world is riddled with highly organized corruption, and why should things be any different here? I'd certainly be happy to be pleasantly surprised. My point is different: even if things turn out as I suspect, IFRX is a clear buy for me. The pipeline is well-developed, and the CR5 inhibitors seem promising. So even if the scenario described above comes to pass, there's still plenty of room in the market for a better competitor. IFRX might not be a tenfold increase anymore, but double-digit share prices are still more than realistic. That's why I'm continuing to buy on dips now.

4 · Reply

Monkey82 Jul. 2 at 3:24 PM

$IFRX Hopefully CMD date announcement soon. Summer is here!

0 · Reply

levystrauss Jul. 2 at 2:26 PM

$IFRX The one thing Niels is good at is raising money and diluting shareholders—I have to admit, he’s one of the best at that, unfortunately!

0 · Reply

levystrauss Jul. 2 at 2:24 PM

$IFRX Even a good product can be ruined by a clumsy CEO who lacks vision and the ability to engage in dialogue with other CEOs. Over the past seven years, Niels has shown himself to be very poor in this regard.

0 · Reply

levystrauss Jul. 2 at 2:23 PM

$IFRX The problem is Niels

0 · Reply

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

2026-05-13T12:32:38.000Z - 7 weeks ago

InflaRx upgraded to Strong Buy from Outperform at Raymond James

2026-05-11T18:30:06.000Z - 7 weeks ago

InflaRx price target raised to $8 from $6 at H.C. Wainwright

May 8, 2026, 8:30 AM EDT - 2 months ago

InflaRx Transcript: Investor update

May 8, 2026, 8:30 AM EDT - 2 months ago

InflaRx Press release: Investor update

May 8, 2026, 8:30 AM EDT - 2 months ago

InflaRx Slides: Investor update

May 8, 2026, 8:15 AM EDT - 2 months ago

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

2026-05-07T03:51:29.000Z - 2 months ago

InflaRx to develop izicopan in AAV

May 6, 2026, 8:30 AM EDT - 2 months ago

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

May 6, 2026, 8:25 AM EDT - 2 months ago

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

2026-05-04T12:09:26.000Z - 2 months ago

InflaRx announces new izicopan pre-clinical data

May 4, 2026, 7:30 AM EDT - 2 months ago

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

May 1, 2026, 7:30 AM EDT - 2 months ago

InflaRx to Report First Quarter 2026 Results on May 7, 2026

Apr 28, 2026, 7:30 AM EDT - 2 months ago

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

2026-04-24T11:41:38.000Z - 2 months ago

InflaRx assumed with an Outperform at Oppenheimer

2026-04-09T11:54:44.000Z - 3 months ago

InflaRx announces new izicopan in vitro findings

Apr 9, 2026, 7:30 AM EDT - 3 months ago

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

Mar 31, 2026, 7:30 AM EDT - 3 months ago

InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium

2026-03-30T12:10:23.000Z - 3 months ago

InflaRx presents vilobelimab data

Mar 30, 2026, 7:30 AM EDT - 3 months ago

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

2026-03-20T11:20:14.000Z - 3 months ago

InflaRx price target lowered to $14 from $22 at Guggenheim

Mar 19, 2026, 9:30 AM EDT - 3 months ago

InflaRx Annual report: Q4 2025

Mar 19, 2026, 9:30 AM EDT - 3 months ago

InflaRx Earnings release: Q4 2025

2026-03-19T11:35:54.000Z - 3 months ago

InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year

Mar 19, 2026, 7:30 AM EDT - 3 months ago

InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

Mar 18, 2026, 7:30 AM EDT - 3 months ago

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

Mar 13, 2026, 5:00 PM EDT - 4 months ago

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 12, 2026, 7:30 AM EDT - 4 months ago

InflaRx to Report Full Year 2025 Results on March 19, 2026

Mar 9, 2026, 9:20 AM EDT - 4 months ago

InflaRx Transcript: Leerink Global Healthcare Conference 2026

Feb 26, 2026, 7:30 AM EST - 4 months ago

InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference

Feb 25, 2026, 8:40 AM EST - 4 months ago

InflaRx Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026, 11:30 AM EST - 5 months ago

InflaRx Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Jan 29, 2026, 7:30 AM EST - 5 months ago

InflaRx Announces Participation in February Investor Conferences

2026-01-08T13:21:00.000Z - 6 months ago

InflaRx to prioritize izicopan as lead asset, reduces workforce by 30%

Jan 8, 2026, 8:00 AM EST - 6 months ago

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

2025-12-30T12:40:39.000Z - 6 months ago

InflaRx outlines data analyses of Phase 3 study for vilobelimab in PG

Dec 30, 2025, 7:30 AM EST - 6 months ago

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

2025-12-11T12:35:44.000Z - 7 months ago

InflaRx announces international nonproprietary name of “izicopan” for INF904

Dec 11, 2025, 7:30 AM EST - 7 months ago

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

2025-12-03T11:53:16.000Z - 7 months ago

InflaRx downgraded to Market Perform from Outperform at Leerink

2025-12-03T11:16:16.000Z - 7 months ago

InflaRx downgraded to Market Perform from Outperform at Leerink

Nov 11, 2025, 2:30 PM EST - 8 months ago

InflaRx Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-11T11:20:32.000Z - 8 months ago

InflaRx price target raised to $8 from $3 at Cantor Fitzgerald

2025-11-11T11:16:27.000Z - 8 months ago

InflaRx price target raised to $9 from $2 at Raymond James

2025-11-11T11:15:24.000Z - 8 months ago

InflaRx price target raised to $7 from $3 at Oppenheimer

2025-11-10T21:11:57.000Z - 8 months ago

InflaRx price target raised to $24 from $3 at Lucid Capital

Nov 10, 2025, 4:00 PM EST - 8 months ago

InflaRx Earnings release: Q3 2025

Nov 10, 2025, 8:00 AM EST - 8 months ago

InflaRx Transcript: Status Update

Nov 10, 2025, 8:00 AM EST - 8 months ago

InflaRx Press release: Status Update

Nov 10, 2025, 8:00 AM EST - 8 months ago

InflaRx Slides: Status Update

Nov 10, 2025, 7:30 AM EST - 8 months ago

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)

Nov 7, 2025, 4:05 PM EST - 8 months ago

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

Oct 21, 2025, 7:20 AM EDT - 9 months ago

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Sep 4, 2025, 9:10 AM EDT - 10 months ago

InflaRx Transcript: Cantor Global Healthcare Conference 2025

Aug 21, 2025, 7:30 AM EDT - 11 months ago

InflaRx Announces Participation in September Investor Conferences

Aug 7, 2025, 7:30 AM EDT - 11 months ago

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 7:00 AM EDT - 11 months ago

InflaRx Earnings release: Q2 2025

Jul 31, 2025, 7:30 AM EDT - 1 year ago

InflaRx to Report Second Quarter 2025 Results on August 7, 2025

Jun 4, 2025, 7:35 AM EDT - 1 year ago

InflaRx Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 1:30 AM EDT - 1 year ago

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

May 22, 2025, 7:30 AM EDT - 1 year ago

InflaRx to Participate in Upcoming Investor Conferences

May 7, 2025, 9:30 AM EDT - 1 year ago

InflaRx Earnings release: Q1 2025

May 7, 2025, 7:30 AM EDT - 1 year ago

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 30, 2025, 7:30 AM EDT - 1 year ago

InflaRx to Report First Quarter 2025 Results on May 7, 2025

Mar 20, 2025, 9:30 AM EDT - 1 year ago

InflaRx Earnings release: Q4 2024

Mar 20, 2025, 9:30 AM EDT - 1 year ago

InflaRx Annual report: Q4 2024

Mar 20, 2025, 7:30 AM EDT - 1 year ago

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Mar 7, 2025, 8:00 AM EST - 1 year ago

InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 28, 2025, 9:00 AM EST - 1 year ago

InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 25, 2025, 7:30 AM EST - 1 year ago

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Feb 18, 2025, 4:01 PM EST - 1 year ago

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 9:45 PM EST - 1 year ago

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 4:01 PM EST - 1 year ago

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

Jan 23, 2025, 7:30 AM EST - 1 year ago

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

Jan 15, 2025, 12:30 PM EST - 1 year ago

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

Dec 20, 2024, 7:30 AM EST - 1 year ago

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Dec 4, 2024, 2:30 PM EST - 1 year ago

InflaRx Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 15, 2024, 7:51 AM EST - 1 year ago

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Nov 11, 2024, 11:00 AM EST - 1 year ago

InflaRx Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 8, 2024, 9:30 AM EST - 1 year ago

InflaRx Earnings release: Q3 2024

Nov 8, 2024, 7:30 AM EST - 1 year ago

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 25, 2024, 7:30 AM EDT - 1 year ago

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

Sep 18, 2024, 9:45 AM EDT - 1 year ago

InflaRx Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 3, 2024, 7:30 AM EDT - 1 year ago

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

Aug 27, 2024, 7:30 AM EDT - 2 years ago

InflaRx Announces Participation in September Investor Events

Aug 8, 2024, 9:30 AM EDT - 2 years ago

InflaRx Earnings release: Q2 2024

Aug 8, 2024, 7:30 AM EDT - 2 years ago

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 7:30 AM EDT - 2 years ago

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

Jun 24, 2024, 8:02 AM EDT - 2 years ago

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

Jun 5, 2024, 12:00 PM EDT - 2 years ago

InflaRx Hosts R&D Event Highlighting the Promise of INF904

May 21, 2024, 2:30 PM EDT - 2 years ago

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

May 8, 2024, 7:30 AM EDT - 2 years ago

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

morgueana Jul. 3 at 6:42 PM

3 · Reply

FlowerInTheCellar Jul. 3 at 4:14 PM

0 · Reply

FlowerInTheCellar Jul. 3 at 1:51 PM

0 · Reply

Monkey82 Jul. 3 at 1:44 PM

$IFRX https://seekingalpha.com/news/4609828-strong-buy-at-under-10-the-highest-quant-rated-bargain-stocks-right-now

0 · Reply

Barkingdogs Jul. 3 at 12:32 PM

$IFRX

0 · Reply

nickmick Jul. 2 at 4:40 PM

4 · Reply

Monkey82 Jul. 2 at 3:24 PM

$IFRX Hopefully CMD date announcement soon. Summer is here!

0 · Reply

levystrauss Jul. 2 at 2:26 PM

$IFRX The one thing Niels is good at is raising money and diluting shareholders—I have to admit, he’s one of the best at that, unfortunately!

0 · Reply

levystrauss Jul. 2 at 2:24 PM

0 · Reply

levystrauss Jul. 2 at 2:23 PM

$IFRX The problem is Niels

0 · Reply

Holten7575 Jul. 2 at 1:45 PM

$IFRX could have been a typo ---think he meant $2.60 --lol

1 · Reply

Barkingdogs Jul. 2 at 1:26 PM

$IFRX going up

0 · Reply

FlowerInTheCellar Jul. 2 at 11:48 AM

$IFRX Found this today. The BARDA study is currently evaluating three different Host-Directed Therapy approaches for ARDS: • **Vilobelimab (InflaRx)** → C5a • **Paridiprubart (Edesa)** → TLR4 • **Bevacizumab** → VEGF In addition, I came across a report on ALT-100, another monoclonal antibody targeting eNAMPT, which is being developed outside the BARDA study. https://www.eurekalert.org/news-releases/1134294 To me, the most interesting part is not the individual drug itself, but the broader picture: there are now at least four different immunological targets being clinically explored as potential therapeutic approaches for ARDS. This suggests that the scientific focus is increasingly shifting toward -Host-Directed Therapies—targeting the dysregulated immune response itself rather than focusing exclusively on the underlying pathogen.

2 · Reply

Barkingdogs Jul. 2 at 1:24 AM

$IFRX I'm quite confident that we are heading for a 3 to 5 trading range very very soon

0 · Reply

JerzeyDevil Jul. 1 at 8:05 PM

$IFRX They want to keep this down I guess 🤷

1 · Reply

StartSlow Jul. 1 at 6:18 PM

$IFRX what will / could be the next possible price boosting and groundbreaking news? What are you’re thoughts? Hoping for short term actions haha 😜

3 · Reply

JerzeyDevil Jul. 1 at 6:04 PM

$IFRX Anyone know; Have any of IFRX management ever purchased shares on the open market?

1 · Reply

JerzeyDevil Jul. 1 at 4:55 PM

$IFRX

0 · Reply

cielo1 Jul. 1 at 4:21 PM

$IFRX nicceee let's finally see that $3++

0 · Reply

Barkingdogs Jul. 1 at 4:04 PM

$IFRX bow wow On June 30, 2026 The Company today announced that it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The Company has initiated this assessment given the recommendation of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) to revoke the marketing authorization for Tavneos in the European Union, announced on June 26, 2026. In addition, the Company announced it intends to engage with EMA regarding both its anti-C5a antibody vilobelimab, which is approved under exceptional circumstances as GOHIBIC in Europe for SARS-CoV-2-induced acute respiratory distress syndrome, in addition to its next-generation oral C5aR inhibitor izicopan. This will be part of the Company’s overall development goal to determine the most efficient development pathway to bring the C5a / C5aR inhibition mechanism to patients. Together, vilobelimab and izicopan provide the Company with a complementary biologic

0 · Reply

rusi1 Jul. 1 at 3:29 PM

$IFRX > 2.6$ for today

0 · Reply

JerzeyDevil Jul. 1 at 3:29 PM

$IFRX Just give us $5 already will ya!

1 · Reply

Market Cap	161.94M
Revenue (ttm)	30,000.00
Net Income (ttm)	-51.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-172,100.01%
Debt to Equity Ratio	0.00

Volume	777,400
Avg Vol	2,143,410
Day's Range	N/A - N/A
Shares Out	72.29M
Stochastic %K	50%
Beta	2.44
Analysts	Strong Sell
Price Target	$8.00